Epidemiological Disease Burden of Female Infertility of Tubal Origin Based on Real-World Health Insurance Claims Data

Author(s)

Elmer D1, Csákvári T2, Kajos L3, Pónusz R3, Pónusz-Kovács D3, Kovács B2, Endrei D2, Boncz I2, Bódis J2
1University of Pécs, Pécs, PE, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Pécs, BA, Hungary

Objectives: More than 10% of the world’s population is affected by infertility which might have social, psychological and economic consequences both for the individual and society. The aim of our study was to determine the epidemiological disease burden of female infertility of tubal origin.

Methods: Data were derived from the financial database of the Hungarian National Health Insurance Fund Administration (NHIFA), for the year 2019. Data analysed included annual patient numbers, case numbers and prevalence of care utilisation per 100,000 population according to age groups. The following health insurance treatment categories were included into our study: general practice care, home care, in- and outpatient care, medical imaging, laboratory diagnostics, drugs and medical aids. Patients with female infertility of tubal origin were identified with the following code of the International Classification of Diseases 10th revision: N97.1.

Results: The highest national patient numbers were in use of pharmaceuticals (818 women) and acute inpatient care (546 women), followed by outpatient care (483 women), and general practice care (244 women). The average age of the patients was 37.3. Based on patient numbers in use of pharmaceuticals, prevalence in 100,000 among women was 16.0 patients. The prevalence showed a significant difference among age groups calculated with the use of pharmaceuticals: 15.3/100,000 (20-29 years), 73.8/100,000 (30-39 years), 30.4/100,000 (40-49 years).

Conclusions: The prevalence of the disease was found to be 16.0 per 100,000 female patients in Hungary in 2019. The highest patient number was found in use of pharmaceuticals and acute inpatient care. The highest prevalence wase observed in the ‘30-39’ and ‘40-49’ age groups.

Conference/Value in Health Info

2022-05, ISPOR 2022, Washington, DC, USA

Value in Health, Volume 25, Issue 6, S1 (June 2022)

Code

EPH122

Topic

Epidemiology & Public Health, Study Approaches

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×